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Available online 21 June 2007Edited by Masayuki MiyasakaAbstract Myeloid dendritic cells (mDCs) play an important
role in the initiation of immune responses to cancer and infec-
tious diseases. Toll-like receptors (TLRs) expressed on mDCs
recognize microbial products to elicit signals for mDC matura-
tion, including cytokine production, antigen-presentation and
induction of eﬀector cells. TLR agonists work as adjuvants to
modulate the function of mDCs. In TLR signaling, MyD88
and TRIF/TICAM-1 are major TLR adaptor molecules, which
when overexpressed are able to transduce downstream signals
without TLR stimuli. We successfully introduced the adaptors
into mouse bone marrowderived mDCs using lentiviral vectors.
Introduction of MyD88 into mDCs in vitro led to the production
of IL-6 and IL-12p40 while introduction of TICAM-1 stimulated
interferon (IFN)-alpha production. Expression of TICAM-1, but
not MyD88, in mDCs slightly induced the co-stimulatory mole-
cule CD86, while signiﬁcant upregulation of CD86 was observed
in response to other TLR stimuli. Both MyD88 and TICAM-1
augmented allogeneic mixed lymphocyte reaction (MLR). Ex
vivo mouse spleen cells pre-exposed to tumor antigen exhibited
antitumor cytotoxicity when incubated with MyD88- or TI-
CAM-1-expressing mDCs. Using mDC adoptive transfer and a
syngeneic mouse tumor implant model, we established an antitu-
mor immunotherapy whereby tumor growth is retarded by adap-
tor-manipulated mDCs.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Myeloid dendritic cells (mDCs) have a potency to produce
cytokines/interferons (IFNs), present antigens and up-regulate
co-stimulatory molecules, which can lead to antibody produc-Abbreviations: DC, dendritic cell; IRES, internal ribosomal re-entry
sequence; mDC, myeloid dendritic cell; MLR, mixed lymphocyte
reaction; pDC, plasmacytoid dendritic cell; TLR, Toll-like receptor
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doi:10.1016/j.febslet.2007.06.019tion and activation of T cells and NK cells [1]. Antigen-present-
ing mDCs play an important role in triggering immune
responses to cancer and infectious diseases [1]. mDCs express
Toll-like receptors (TLRs) that recognize bacterial or viral
ligands and deliver signals for mDC maturation [2]. MyD88
[3,4] and TRIF/TICAM-1 [5,6] are major TLR adaptor mole-
cules, and transduce downstream signals by their overexpres-
sion.
TLRs have been identiﬁed as a family of receptors that con-
sist of >10 protein members both in humans and mice [2,7].
Each TLR recognizes diﬀerent microbial pattern molecules.
When the TLR recognizes its ligand, it signals through the
adaptor molecule that associates with the cytoplasmic domain
of the TLR [2,7]. These adaptors are involved in activation of
transcription factors. In mDCs, NF-jB and IRF-3 are acti-
vated [8,9] and in plasmacytoid dendritic cells (pDCs) NF-
jB and IRF-7 are activated [10]. Production of cytokines
(IL-6, IL-12, TNFa, etc.) and IFN-a/IFN-b are regulated by
NF-jB and IRF-3/IRF-7, respectively [11]. Thus, the adaptors
participate in selective activation between the diﬀerent func-
tions of mDCs. Ultimately, CTL induction and NK activation
are dependent upon the adaptor pathways in mDCs [12,13].
The presence of a variety of eﬀector modes induced by TLRs
suggests that in maturation of mDCs, the TLR signals act dif-
ferentially on their functional output depending upon the
adaptors selected. In fact, cytokine/interferon proﬁles, CD83/
CD86 up-regulation and NK/CTL induction represent mark-
ers for diﬀerential maturation of mDCs. Thus, TLR ligands
such as polyI:C [13], CpG [14,15], BCG-CWS [16], and imiqui-
mod [17,18] can induce distinct immune responses and may act
as adjuvants with multiple functions. Some TLR ligands have
in fact been applied with tumor antigen for immunotherapy
against cancer. On the other hand, recent reports have sug-
gested that TLRs are expressed by various cells [19] such as
NK [20], B[21] and regulatory T cells [22], in addition to the
DCs. Thus, TLR ligands directly aﬀect not only the initial re-
sponse of DCs but also later activation and regulation of var-
ious immune cells.
mDCs are the most useful tool in cancer immunotherapy, be-
cause they can induce lymphocyte proliferation that would
damage the host tumor in an antigen-speciﬁc manner. Several
models of DC therapy for cancer have been proposed. Themod-
els include mDCs expressing cytokines by gene-transfection,blished by Elsevier B.V. All rights reserved.
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vants such as TLR ligands. The eﬀectiveness of mDC therapies
has been tested in animals, and some of them have been evalu-
ated for clinical applications. These studies encouraged us to
establish methods for inducing tumor-speciﬁc CTL responses
and reciprocal activation of NK cells by mDC manipulation.
In this communication, we generated mouse mDCs that con-
stitutively express MyD88 or TICAM-1 and applied them to
antitumor immunotherapy in a mouse syngeneic tumor im-
plant model. Our results suggest that each adaptor confers dif-
ferent responses on the mDCs in vitro and in tumor-bearing
mice in vivo. Adoptive transfer of mDCs that overexpress
MyD88 or TICAM-1 into tumor-bearing mice induced retar-
dation of tumor growth in the mouse implant tumor.
2. Materials and methods
2.1. Reagents
FCS was purchased from Bio Whittaker (Walkersville, MD). Mouse
granulocyte-macrophage colony-stimulating factor (GM-CSF) and
interferon (IFN)-cwere from PeproTech EC Ltd. (London, UK). Lipo-
polysaccharide (LPS) (Escherichia coli O111:B4) was supplied by SIG-
MA/Aldrich Chemical company (St. Louis, MO). Lympholyte-M was
obtained from Cedarlane (Ontario, Canada). Enzyme-linked immuno-
sorbent assay (ELISA) kits for IL-6, IL-12p40 and IFN-a were from
Biosource (Camarillo, CA). [3H]-thymidine was from Amersham Bio-
sciences (Piscataway, NJ). Fluorescein isothiocyanate (FITC)-conju-
gated anti-mouse CD86 and isotype control antibodies [Armenian
Hamster IgG (FITC)] were purchased from eBioscience (San Diego,
CA). Mouse CD90 microbeads were fromMiltenyi Biotec (Auburn, CA).
2.2. Cells
B16D8 was established in our laboratory as a sub-line of the B16
melanoma cell line [23]. This sub-line was characterized by its low or
virtually no metastatic properties when injected subcutaneously into
syngeneic C57BL/6 mice [24]. This B16 sub-line barely expressed
MHC class I but in response to IFN-c expressed it to a certain extent
[13]. Cells were incubated with 100 U/ml of IFN-c for 24 h at 37 C for
surface-expression of class I, and used as target cells.
2.3. Construction of lentiviral vector and preparation of virus particle
We used a gene-expression kit, Lenti-viral system (Invitrogen, Carls-
bad, CA). At ﬁrst, to check transfection eﬃciency, a sequence of
hrGFP with the multi-cloning site and internal ribosomal re-entry se-
quence (IRES) was cloned from pIRES-hrGFP-1a vector (Stratagene,
LA Jolla, CA) by PCR and placed into the cloning site of pLenti6/V5-
D-TOPO vector (Invitrogen) by TOPO-cloning system. This vector
was named as pLenti-IRES-hrGFP.
MouseTicam-1 andMyd88 cDNAswere isolated from cDNA library
of RAW cell as described previously [5]. In most experiments, a cDNA
encoding the N-terminal region of TICAM-1 (TICAM-1 N-terminal)
(1–550 amino acids) [25] was employed instead of the full-length TI-
CAM-1 cDNA, since the full-length TICAM-1 expression led to cell
apoptosis within 8 h after transfection [26]. The cDNAs were subcloned
and sequenced for conﬁrmation. The cDNAs encoding MyD88, full
length of TICAM-1 and N-terminal region of TICAM-1, were ligated
into pLenti-IRES-hrGFP vector at the site of EcoRI and XhoI and
named as pLenti-MyD88-IRES-GFP, pLenti-TICAM-1-IRES-GFP,
pLenti-TICAM-1N-IRES-GFP. The primer sequence used for PCR
are as follows: MyD88, sense 5 0-ggaattcaccatgtctgcgggagacccccg-3 0,
antisense 5 0-ccgctcgaggggcagggacaaagccttggc-3 0; TICAM-1, sense 5 0-
ggaattcaccatggataacccagggccttc-3 0, antisense 5 0-ccgctcgagctctggagtct-
caagaagggg-3 0; TICAM-1 N-terminal (1–550), antisense 5 0-
ccgctcgagggttctggcctcctgcgcttt-30; multi-cloning site and IRES-hrGFP,
sense 5 0-caccatgggaattcgcatgcgtcgactcgaggact-3 0, antisense 5 0-ttacacc-
cactcgtgcaggctgcccagggg-30. PCR was performed 30 cycles as follows:
denature for 30 s at 95 C, anneal for 30 s at 55 C and extend for
1 min at 72 C by using KOD plus enzyme (TOYOBO, Japan). Samples
were extended for an additional 5 min at 72 C.
Four plasmids (one of these pLenti vectors, pLP1, pLP2, pLP/
VSVG) were transfected into 293 FT packaging cells, and the viral par-ticles for transfection were prepared according to the manufacturer’s
protocol. The virus particles were concentrated by centrifugation of
20000 rpm at 4 C for 2 h. After the precipitation was resuspended
in RPMI1640 as the virus concentrated solution, the solution was sub-
divided to store at 80 C.
2.4. Transfection eﬃciency
The transfection eﬃciency was assessed by ﬂuorescence of GFP li-
gated in the vector of the lentivirus, and the rate of the positive cell
was determined by FACS in comparison with that of non-infected
cells. The indicated volume of virus concentrated solution was added
to 293 FT cells (5 · 105 cell/500 ll of culture medium with 5 lg/ml
polybrene (Specially Media, Phillipsburg, NJ) in 24 well plate) and
incubated for 12 h. These cells were cultured for 36 h additionally in
fresh medium after wash. Then, the ﬂuorescence intensities of the cells
were assessed by FACS. Transduction eﬃciency of mDCs were ana-
lyzed under the same conditions as that of 293 FT cells.2.5. MLR assay
Mouse mDCs were derived form bone marrow of C57BL6 and
appropriately manipulated as described in the text. mDCs (5 · 104
cells) were cultured with 105 CD90-positive T cells isolated from spleen
of BALB/c mice by MACS beads in 96-well cell culture plates in 200 ll
of culture medium for 72 h. Half of the medium was replaced with
fresh medium containing [3H]-thymidine (1 lCi/well). Then the cells
and medium were harvested separately using a cell harvester, and the
radioactivity was measured by MicroBeta (Perkin–Elmer, Foster City,
CA) with solid scintillator.2.6. Preparation of mouse bone marrow-derived mDCs
Wild-type female C57BL/6 and BALB/c mice were purchased from
Japan Clea (Tokyo, Japan). Bone marrow-derived mDCs were pre-
pared as reported [27] with minor modiﬁcations. mDCs were cultured
in RPMI-1640 containing 10 ng/ml mouse GM-CSF, 50 lM 2-ME,
10 mM HEPES and 10% FCS.2.7. FACS analysis and ELISA
For FACS analysis of CD86 expression levels, cells were suspended
in PBS containing 0.1% sodium azide and 1% FCS and then incubated
for 30 min at 4 C with ﬂuorescence-labeled mAbs. Cells were washed
and their ﬂuorescence intensities were measured by FACS. For FACS
analysis to check transduction eﬃciency, cells were ﬁxed with 0.5%
paraformaldehyde after wash, and resuspended in PBS. For ELISA,
samples were stored at 80 C. Their levels were measured according
to the manufacture’s protocol.2.8. Dendritic cell (DC) therapy
The protocol of animal studies is shown in Fig. 4a. The doses of
virus preparations were adjusted by titration assay to make 50% of
293 FT cells GFP positive (ED50). The ED50 doses of virus were cul-
tured with mouse mDCs for 12 h as in the conditions employed for 293
FT cells (5 · 105 cells/500 ll in a 24-well plate). mDCs were then
washed and suspended in fresh culture medium for additional culture
for 12 h (total 24 h). Tumor debris was prepared from B16 cells by 3-
cycle freeze-thaw and the B16 debris (corresponding to 2.5 · 105 B16
cells/well) was co-incubated with lentivirus-bearing mDCs for last
6 h. After mDCs were loaded with tumor debris, cells were washed,
and then suspended in PBS (106 cells/200 ll). For tumor implantation,
C57BL/6 mice were shaved at the ﬂank and injected subcutaneously
with 200 ll of 6 · 105 syngeneic B16D8 melanoma cells in PBS (indi-
cated as Day 0). Thereafter, mDC treatment was performed three
times on days 12, 16 and 19; mDCs (106 cells) bearing TLR adaptor
and tumor debris were injected subcutaneously around the trans-
planted tumor in mice. Tumor volumes were measured at regular inter-
vals using a caliper every 2 days. Tumor volume was calculated using
the formula: Tumor volume (cm3) = (long diameter) · (short diame-
ter) · (short diameter) · 0.4.2.9. Cytotoxic assay
Debris of B16D8 cells (106 cells) was prepared by freeze-thaw for
immunization. C57BL/6 mice were subcutaneously immunized with
the debris twice on day 14 and 7. On day 0, the mice were sacriﬁced
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with MACS beads by positive selection. To test the eﬀect of antigen
pulse on mDC-mediated tumor cytotoxicity of mouse splenocytes,
mDCs were transduced with TICAM-1 N or MyD88 as above and
in Fig. 4a. Adaptor-expressing mDCs thus prepared were incubated
for 24 h with the splenocytes in the presence or absence of the antigen
(B16 debris). Then, B16D8 cells pretreated with IFN-c and labeled
with 51Cr (12) were added to the mDC-splenocyte mixture at the E/T
ratio = 100. Eighteen hours later, B16D8 killing was determined by
51Cr release.3. Results
Since mDCs proliferate poorly in culture and retrovectors
do not eﬃciently transduce mDCs, a Lenti-viral gene expres-
sion system (Invitrogen, Carlsbad, CA) was used to introduce
TLR adaptors into mouse mDCs. pLenti-IRES-GFP vector
from pLenti6/V5-D-TOPO vector (Invitrogen) and pIRES-
hrGFP-1a vector (Stratagene, LaJolla, CA) were prepared
for this purpose (Fig.1a). The empty vector was used as a con-
trol. cDNAs of mouse TLR adaptors, Myd88 and Ticam-1,
were inserted into the multi-cloning site of this vector (Fig. 1a).
It has been reported that the C-terminal region of TICAM-1
recruits receptor-interacting protein 1 (RIP1) and caspases
leading to apoptosis within 8 h after gene transduction [26].
In fact, most of the 293 FT packaging cells with full-length TI-
CAM-1 died within 24 h after transduction (data not shown).
To circumvent cell apoptosis, the cDNA encoding an N-termi-
nal region (1–550 amino acid) of TICAM-1 including the start
methionine and the Toll-IL-1 homology (TIR) domain was li-Fig. 1. Preparation of lentivirus particles containing TLR adaptor
gene. (a) Construction of pLenti-IRES-GFP vector. Sequence of multi-
cloning site and hrGFP isolated form pIRES-hrGFP (stratagene) by
PCR were constructed into pLenti6/V5 D-TOPO vector (invitrogen)
by TOPO-cloning system. (b) Isolation of mouse TICAM-1 N-
terminal region. Full-length of mice TICAM-1 was composed of 732
amino acids. The TIR domain, which participates in molecular
association with TLR3, spans the region of 399–548 amino acid. The
DNA sequence of TICAM-1 (1–550 amino acid) was isolated as
TICAM-1 N-terminal.gated into the vector (Fig. 1b). This region is suﬃcient for
recruiting NAK-associated protein 1 (NAP1) followed by acti-
vation of the promoter of IFN-b [25] without inducing apop-
tosis. When virus particles were prepared by transfection of
the pLenti-TICAM-1N-IRES-GFP into 293 FT cells, the cells
did not die within 24 h.
Virus titer was evaluated by ED50 of 293 FT cells, where the
amount of virus that induced GFP expression in 50% of
5 · 105 293 FT cells suspended in 500 ll of culture media
was determined (Fig. 2a). Then, using the same ED50 dose,
mDCs were infected with lentivirus. The transfection eﬃcien-
cies of control virus, virus with Myd88, and virus with Ti-Fig. 2. Transfection eﬃciency of the lentivirus preparation. (a)
Titration assay of lentivirus prepared with 293 FT cells. Titration
assay was performed under the conditions of manufacture’s protocol
(5 · 105 cells/500 ll/24 well plate). Indicated volumes of the virus
preparations were added to cells and incubated for 12 h. Then, cells
were washed and cultured in fresh medium for 36 h. The cells were
collected and analyzed by FACS. Percentages of GFP-positive cells are
shown in the inset. (b) Lentiviral transfection into bone marrow-
derived mDCs. The ED50 doses of the virus preparations were
determined with 293 FT cells and the ED50 doses were added to mDCs
as in 293 FT cells. The percentages of GFP-positive cells (left), and
mean ﬂuoresence intensities of CD86 expression in GFP-negative
(middle) and GFP-positive cells (right) are shown. One of the three
similar experiments is shown.
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(Fig. 2b). After treatment of mDCs with virus particles, up-
regulation of the CD86 co-stimulatory molecule was observed,
irrespective of the inserted cDNA. When mDCs infected with
virus (i.e. GFP-positive cells) were stimulated with LPS, the
levels of CD86 were further up-regulated (Fig. 2b). GFP-neg-
ative and lentivirus-negative mDCs were barely mature
according to the CD86 expression levels. Slight CD86 up-reg-
ulation was observed in GFP-positive mDCs expressing Ti-Fig. 3. The characterization of TLR adaptor over-expressed mDCs.
The production of IL-12p40 (a), IL-6 (b), interferon-a (c) by TLR
adaptor-overexpressing mDCs (a and b: 48 h, c: 24 h). mDCs
overexpressing MyD88 produced IL-12p40 and IL-6, but the mDCs
overexpressing TICAM-1 produced interferon-a. (d) Allogeneic mixed
lymphocyte reaction assay. CD90-positive T cells derived from BALB/
c mice were co-cultured with mDCs derived from the bone marrow of
C57BL6 mice for 72 h. Overexpression of TLR adaptors in mDCs were
conﬁrmed by Ab staining (not shown). P < 0.05 in MyD88-expressing
mDCs, while P = 0.14 in TICAM-1-expressing mDCs by student t-test.cam-1, but their CD86 levels were not very high compared to
that observed in mDCs transduced with Myd88-bearing or
the control virus. The up-regulation of CD86 was not a speciﬁc
response to the overexpression of MyD88 in mDCs.
We also examined the production of cytokines or IFNs by
mDCs transduced with MyD88 or TICAM-1 since cytokine/
IFN are possible maturation markers for mDCs. High levels
of IL-6 and IL12p40 were predominantly detected in the cul-
ture supernatants of MyD88-expressing mDCs (Fig. 3a and
b), whereas the production of IFN-a was augmented in the cul-
ture supernatant of TICAM-1-expressing mDCs (Fig. 3c). In
the mixed lymphocyte reaction (MLR) experiment, no large
diﬀerence between these two mDCs was observed. In mDCsFig. 4. Application of mDCs overexpressing TLR adaptors to DC
therapy for cancer. (a) The protocol of DC therapy. mDCs over-
expressing MyD88 or TICAM-1 were prepared as in Fig. 2. Tumor
debris was prepared from B16 cells by 3-cycle freeze-thaw and co-
incubated with lentivirus-bearing mDCs for last 6 h. (b) Eﬀect of
mDCs overexpressing TLR adaptor on regression of implanted tumor.
Manipulated mDCs (106 cells) were injected intraperitoneally into
C57BL/6 mice three times per week (open arrows). Tumor growth was
monitored in mouse groups treated with mDCs having indicated
lentiviruses. (c) B16 cytotoxicity by mouse splenocytes was enhanced
by adaptor-transduced mDCs. CD8+ eﬀector cells were isolated from
the spleen of C57BL/6 mice immunized with debris of B16 cells that
had been treated with IFN-c. Adaptor-transduced mDCs were
manipulated as in Fig. 4a. Eﬀector cells were co-cultured for 24 h
with manipulated mDCs which were pretreated with (solid bars) or
without (open bars) B16 debris. Then, the 51Cr-labeled B16 cells were
added as target and incubated for additional 18 h at the E/T
ratio = 100. Cytotoxicity was determined by the released 51Cr.
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mented compared to the mock-infected mDCs (Fig. 3d).
mDCs transduced with the TLR adaptor gene were em-
ployed as a DC therapy for cancer in a mouse model, and
the therapeutic eﬀect of the mDCs on tumor regression was
examined. The schedule of mDC manipulation/therapy is
shown in Fig. 4a. The manipulated mDCs retarded the growth
of implanted tumors (Fig. 4b). This antitumor eﬀect was neg-
ligible in the control group consisting of mDCs infected with
control virus. However, an antitumor eﬀect was observed in
the group consisting of mDCs that expressed the TICAM-1
N. Furthermore, the group consisting of mDCs transfected
with MyD88 triggered a more signiﬁcant retardation of tumor
growth than the group consisting of mDCs transfected with
TICAM-1N.
We tested whether the adaptor-transduced mDCs augment
antigen-dependent or non-speciﬁc cytotoxicity. Splenocytes
containing CD8+ lymphocytes were prepared from C57BL/6
mice immunized with B16 debris. The splenocytes were incu-
bated with mDCs expressing MyD88 or TICAM-1 and their
cytotoxic activities were measured with B16D8 cells that had
been treated with IFN-c for MHC class I expression.
MyD88 in mDCs tended to augment antigen-speciﬁc lympho-
cyte-mediated B16 cytotoxicity whereas TICAM-1 in mDCs
up-regulated B16 cytotoxicity in an antigen-independent man-
ner (Fig. 4c). Thus, the MLR potency in vitro does not simply
reﬂect the in vivo tumor-regression activity by mDCs. MyD88
and TICAM-1 allow mDCs to mature diﬀerentially inducing
cytotoxic lymphocytes mainly in an antigen-dependent and
an independent fashion, respectively.4. Discussion
Following infection with bacteria and viruses, TLRs recog-
nize microbial components and activate mDCs [2,7]. IFNs
and cytokines that are produced by activated mDCs induced
the inﬂammatory response leading to activation of the immune
system. Maturation of mDCs is characterized by CD83/CD86
levels and induction of eﬀector cells. It is becoming clear that
antitumor responses arise after mDCs prime with antigen as
well as sense inﬂammatory signals. However, how TLRs par-
ticipate in sensitizing mDCs to induce an antitumor eﬀect re-
mains unclear [28]. This study ﬁrstly focused on the
diﬀerence between the MyD88 and TICAM-1 (TRIF) pathway
in the induction of antitumor potential in mDCs. The second
point of this study is that not only mDCs but also cancer cells
express TLRs that promote tumor cell growth in response to
inﬂammatory stimuli [29]. Methods for more speciﬁc activa-
tion of TLRs exclusively on mDCs should be explored.
Here, we propose a method for speciﬁcally activating mDCs
by introducing TLR adaptor molecules into mouse mDCs
using a lentivirus vector. The diﬀerential activation phenotype
was obtained depending on the adaptor employed. CD86 was
up-regulated in mDCs expressing TICAM-1 but not in mDCs
expressing MyD88. MyD88 allowed mDCs to induce IL-6 and
IL12p40 and augmented MLR, whereas TICAM-1 (N-termi-
nal) facilitated mDCs by potentially inducing type I IFN and
augmenting MLR. Perhaps, the MLR activity does not always
reﬂect in vivo antitumor activity: MyD88 preferentially ma-
tures mDCs with ability to induce antigen-dependent lympho-
cyte-mediated cytotoxicity whereas TICAM-1 matures mDCsto induce NK-like cytotoxicity. Either of these mDCs exhib-
ited in vivo tumor-regression activity irrespective of their phe-
notypic diﬀerences. Hence, the level of CD86 does not always
reﬂect the antitumor potency of mDCs.
Although the retardation of tumor growth was signiﬁcant in
this mDC adoptive-transfer therapy, we observed low protein-
expression eﬃcacy (50%) and apoptosis-inducing properties
of the gene-transduced mDCs. Since these technical problems
were particularly prominent in TICAM-1-expressing mDCs,
we employed the TICAM-1 N-terminal construct. Regardless
of these technical problems, TICAM-1 N-terminal confers un-
ique properties on mDCs, which are consistent with previous
reports using the full-length TICAM-1, suggesting that
polyI:C-mediated TLR3 activation results in cross-priming
and mDC-mediated NK activation [30,31]. The antitumor po-
tential due to activation of the TLR3-TICAM-1 pathway may
be closely linked to mDC-mediated NK activation.
Our previous ﬁndings using TLR adaptor gene-knock out
mice indicated that in mDCs, the TICAM-1 pathway is in-
volved in NK activation [13], while the MyD88 pathway solely
induces CTL resulting in tumor regression [12]. We obtained
these results using C57BL/6 mice with B16 melanoma, and
have employed the same system in the present study. TI-
CAM-1 directly binds to TLR3 [5] and activates virus-acti-
vated kinases via NAP1 [25]. It has been reported that IRF-3
and the IFN-b promoter are constitutively activated by over-
expression of TICAM-1 [5]. Thus, TICAM-1 is crucial in this
pathway. Indeed, in mDCs the protein level of TICAM-1 is
usually minimal, and is therefore insuﬃcient to induce type I
IFNs [32]. The antitumor potential of TICAM-1-expressing
mDCs may be attributable to induction of type I IFN and
antitumor eﬀectors including NK. In fact, the cells harvested
from the draining lymph nodes of tumor-implanted mice with
mDCs expressing TICAM-1, exhibited cytotoxicity against
YAC-1 (an NK target) and parental B16 melanoma (data
not shown).
The functional interpretation of the data for mDCs over-
expressing MyD88 is more complicated. Since MyD88 is an
adaptor molecule of not only the TLR but also IL-1 and IL-
18 receptors [3,4], mDCs expressing MyD88 are implicated
in more complex inﬂammatory reactions. Consistent with this,
adoptive transfer of MyD88-expressing mDCs induced a supe-
rior antitumor eﬀect than TICAM-1-expressing mDCs. How-
ever, since no appropriate method for determining CTL
activity in the lentiviral mDC manipulation system, we were
unable to detect the antitumor CTL activity generated in mice
receiving DC therapy (data not shown).
The lentivirus vector is an eﬃcient tool for gene delivery into
diﬀerentiated cells [33]. TLR adaptors and tumor antigens can
be inserted into this vector and overexpressed in mDCs. Eﬃ-
ciency of transfection can be easily monitored by insertion of
the IRES and GFP downstream of the objective genes. If the
tumor antigen is already known, the antigen sequence can be
inserted downstream of the TLR gene and IRES insertion site.
CTL activation following antigen uptake, occurs through
cross-presentation by mDCs stimulated with TLR ligands or
adaptor input. Although the mechanism by which cross-prim-
ing is induced in TLR-treated mDCs is uncertain, tumor anti-
gens are eﬃciently presented on MHC class I by the normal
antigen-processing pathway. Taken together, in vivo adoptive
transfer studies show that these mDCs are able to regress syn-
geneic tumors that have been implanted in mice.
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For example, vaccine enhancement has been accomplished by
the addition of a foreign helper protein KLH [34]. Potent pro-
tective immunity has been induced by administration of tumor
RNA-pulsed mDCs [35]. An eﬀective therapeutic potential has
been obtained using mDCs with a modiﬁed IL-12 gene [36].
These last two reports suggest that the intratumoral route is
more eﬀective than the other extratumoral routes [35,36]. Here,
we propose a strategy of specifying the mode of maturation of
mDCs by manipulating TLR signaling. It is possible that a
more eﬀective therapeutic gain is obtained by further revision
of our administering protocol, schedule, route, and the number
of mDCs used.
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